Breaking News Instant updates and real-time market news.

OCUL

Ocular Therapeutix

$6.31

-0.2 (-3.07%)

, REGN

Regeneron

$373.47

-12.58 (-3.26%)

07:06
10/13/16
10/13
07:06
10/13/16
07:06

Ocular Therapeutix outlines strategy for sustained release intravitreal depots

Ocular Therapeutix (OCUL) provided an update on the company's development strategy for its sustained release intravitreal depot technology for the treatment of serious retinal diseases. The company is currently developing proprietary sustained-release hydrogel-based drug delivery depots for intravitreal injection that can be formulated with both small and large molecule pharmaceuticals, such as tyrosine kinase inhibitors and protein-based anti-vascular endothelial growth factors respectively, with the goal of delivering sustained and therapeutic levels of drugs to targeted ocular tissues. The goal of the company's intravitreal depot dual development program is to reduce the frequency of injections that are currently the standard of care for the treatment of wet AMD, DME and other retinal diseases. Accordingly, Ocular Therapeutix also announced today that it has entered into a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals (REGN) for the development of a sustained release formulation of Regeneron's VEGF trap, aflibercept, for the treatment of wet age-related macular degeneration and other serious retinal diseases. Regeneron's aflibercept is currently approved by the U.S. FDA for certain indications under the brand name EYLEA. Per the agreement, Ocular Therapeutix retains all rights to develop its sustained-release hydrogel-based drug delivery platform with all other non-VEGF targeting compounds as well as with small molecule pharmaceuticals, including TKIs, for other retinal diseases.

OCUL

Ocular Therapeutix

$6.31

-0.2 (-3.07%)

REGN

Regeneron

$373.47

-12.58 (-3.26%)

  • 30

    Oct

  • 04

    Nov

  • 29

    Nov

  • 29

    Mar

OCUL Ocular Therapeutix
$6.31

-0.2 (-3.07%)

06/06/16
COWN
06/06/16
NO CHANGE
Target $60
COWN
Outperform
Ocular OTX-DP data miss 'meaningless' to Outperform thesis, says Cowen
Cowen said that while any clinical trial failure of any kind is always a disappointment, the OTX-DP miss in allergic conjunctivitis reported by Ocular Therapeutix is "meaningless" to the firm's thesis, which is predicated "nearly entirely" on the OTX-TP opportunity for the treatment of glaucoma. The firm keeps an Outperform rating and $60 price target on Ocular shares.
06/07/16
MSCO
06/07/16
NO CHANGE
Target $16
MSCO
Overweight
Ocular Therapeutix weakness an overreaction, says Morgan Stanley
Morgan Stanley analyst Andrew Berens said the initial investor reaction to the failure of the second Phase III trial for Dextenza in allergic conjunctivitis appears extreme. Berens said he assigned little direct value for the allergy opportunity and does not see a read through to the post-op indication. The analyst said the focus remains on Dextenza's July 24 PDUFA in post surgical pain and maintains his Overweight rating on Ocular and $16 price target.
07/26/16
RBCM
07/26/16
NO CHANGE
RBCM
Ocular Therapeutix risk/reward still positive, says RBC Capital
After the FDA issued a complete response letter for Ocular's Dextenza, RBC Capital analyst Adnan Butt notes that the agency did not ask for more safety or efficacy data about the drug. According to the analyst, the company has already issued a response to the letter, and the FDA's reply could come in one to three months. Butt thinks that the stock could still advance if Dextenza and a number of its other drugs are approved. The analyst trimmed the price target on the shares to $38 from $40 but keeps an Outperform rating on the stock.
08/11/16
JMPS
08/11/16
INITIATION
Target $21
JMPS
Outperform
Ocular Therapeutix initiated with an Outperform at JMP Securities
Target $21.
REGN Regeneron
$373.47

-12.58 (-3.26%)

09/21/16
RBCM
09/21/16
NO CHANGE
RBCM
Regeneron Fasinumab deal positive, says RBC Capital
After Teva (TEVA) agreed to partner with Regeneron (REGN) on its Fasinumab pain killer, RBC Capital analyst Adrian Butt says that the deal validates the "under the radar" drug. The analyst says that Regeneron could make "many future deals" if its pipeline remains productive. Butt writes that the terms of the deal are attractive for Regeneon, and the analyst keeps a $648 price target and Outperform rating on the stock.
09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
10/03/16
ROTH
10/03/16
NO CHANGE
Target $520
ROTH
Buy
Regeneron has 'solid' growth prospects, upside potential, says Roth Capital
After Regeneron (REGN) and Sanofi (SNY) released positive results from their Dupixent Phase 3 trials, SOLO 1 and SOLO in patients with atopic dermatitis, Roth Capital analyst Joseph Pantginis notes that clinical studies of Dupixent for additional atopic and allergic diseases are progressing and says he believes Regeneron's shares are poised for upside on upcoming catalysts. Moreover, the analyst says Regeneron has "solid" growth prospects based on approved and late stage products, deep pipeline, expansion of indications for current products, strong partners, and strong cash management. He reiterates a Buy rating and $520 price target on Regeneron's shares.
10/04/16
JPMS
10/04/16
NO CHANGE
Target $110
JPMS
Overweight
Ophthotech price target raised to $110 from $95 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Ophthotech to $110 from $95 citing the elimination of Regeneron (REGN) from the Wet age-related macular degeneration space following its trial failure. Ophthotech closed yesterday down $2.56 to $43.57. The stock is down 20% since last Friday amid mechanism concerns following Regeneron's phase 2 data, Rama tells investors in a research note. The analyst views the weakness in Ophthotech as a buying opportunity. There are important mechanistic differences between the company's Fovista and Regeneron's REGN2176-3, and early phase 1 data for Fovista "are comparatively more compelling," the analyst contends. He points out that the Phase 3 results with Fovista + Lucentis combination therapy are expected this quarter. The analyst keeps an Overweight rating on Ophthotech.

TODAY'S FREE FLY STORIES

JPM

JPMorgan

$93.78

-0.34 (-0.36%)

, PNC

PNC Financial

$132.92

-0.6 (-0.45%)

10:40
09/26/17
09/26
10:40
09/26/17
10:40
Hot Stocks
Deutsche moves to the sidelines on JPMorgan, PNC »

Shares of JPMorgan (JPM)…

JPM

JPMorgan

$93.78

-0.34 (-0.36%)

PNC

PNC Financial

$132.92

-0.6 (-0.45%)

GS

Goldman Sachs

$230.47

0.21 (0.09%)

WFC

Wells Fargo

$54.07

0.04 (0.07%)

MS

Morgan Stanley

$47.55

-0.19 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 03

    Oct

  • 12

    Oct

  • 13

    Oct

  • 13

    Oct

  • 17

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

RGEN

Repligen

$43.22

-0.54 (-1.23%)

, GE

General Electric

$25.12

0.01 (0.04%)

10:40
09/26/17
09/26
10:40
09/26/17
10:40
Recommendations
Repligen, General Electric analyst commentary  »

Stephens sees GE resin as…

RGEN

Repligen

$43.22

-0.54 (-1.23%)

GE

General Electric

$25.12

0.01 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Sep

  • 02

    Oct

  • 30

    Nov

WEN

Wendy's

$14.91

-0.13 (-0.86%)

10:40
09/26/17
09/26
10:40
09/26/17
10:40
Options
Bullish flow in Wendy's as call buyers gobble up new positions »

Bullish flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 22

    Oct

10:40
09/26/17
09/26
10:40
09/26/17
10:40
General news
Fed governor Brainard steered clear of policy »

Fed governor Brainard…

10:35
09/26/17
09/26
10:35
09/26/17
10:35
General news
U.S. consumer confidence slipped to 119.8 »

U.S. consumer confidence…

CATM

Cardtronics

$26.10

-3.17 (-10.83%)

10:34
09/26/17
09/26
10:34
09/26/17
10:34
Downgrade
Cardtronics rating change  »

Cardtronics downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$35.48

-0.03 (-0.08%)

10:30
09/26/17
09/26
10:30
09/26/17
10:30
Options
Bullish option flow in Pfizer »

Bullish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 18

    Oct

  • 31

    Oct

  • 08

    Nov

10:30
09/26/17
09/26
10:30
09/26/17
10:30
General news
U.S. Richmond Fed's manufacturing index rose to 19 in September »

U.S. Richmond Fed's…

NSRGY

Nestle

$83.75

0.88 (1.06%)

, VZ

Verizon

$49.83

-0.075 (-0.15%)

10:29
09/26/17
09/26
10:29
09/26/17
10:29
Hot Stocks
Nestle sets new profit targets, though stance on L'Oreal stake unchanged »

Shares of Nestle (NSRGY)…

NSRGY

Nestle

$83.75

0.88 (1.06%)

VZ

Verizon

$49.83

-0.075 (-0.15%)

LRLCY

L'Oreal

$43.13

-0.19 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 19

    Oct

RGEN

Repligen

$43.22

-0.54 (-1.23%)

, GE

General Electric

$25.09

-0.025 (-0.10%)

10:28
09/26/17
09/26
10:28
09/26/17
10:28
Recommendations
Repligen, General Electric analyst commentary  »

GE launch to weight on…

RGEN

Repligen

$43.22

-0.54 (-1.23%)

GE

General Electric

$25.09

-0.025 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Sep

  • 02

    Oct

  • 30

    Nov

ADDYY

adidas

$113.80

-1.22 (-1.06%)

, NKE

Nike

$53.21

-0.025 (-0.05%)

10:28
09/26/17
09/26
10:28
09/26/17
10:28
Periodicals
Adidas, Nike employees reportedly named in FBI corruption probe »

The head of sports…

ADDYY

adidas

$113.80

-1.22 (-1.06%)

NKE

Nike

$53.21

-0.025 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

  • 04

    Oct

CCL

Carnival

$65.80

2.3 (3.62%)

10:27
09/26/17
09/26
10:27
09/26/17
10:27
Hot Stocks
Carnival says booking volumes for 2018 ahead of prior year »

Says Booking volumes for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

10:25
09/26/17
09/26
10:25
09/26/17
10:25
General news
The 3.4% August U.S. new home sales drop »

The 3.4% August U.S. new…

X

U.S. Steel

$24.36

0.305 (1.27%)

10:21
09/26/17
09/26
10:21
09/26/17
10:21
Periodicals
U.S. Steel spokesperson tells Bloomberg company has not sold Slovak unit »

Bloomberg cites U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

X

U.S. Steel

$24.36

0.305 (1.27%)

10:20
09/26/17
09/26
10:20
09/26/17
10:20
Periodicals
Chinese company nearing acquisition of U.S. Steel's Kosice, Spectator reports »

The sale of U. S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DWDP

DowDuPont

$70.44

0.1 (0.14%)

, LLEX

Lilis Energy

$4.44

0.09 (2.07%)

10:20
09/26/17
09/26
10:20
09/26/17
10:20
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

DWDP

DowDuPont

$70.44

0.1 (0.14%)

LLEX

Lilis Energy

$4.44

0.09 (2.07%)

ALDR

Alder Biopharmaceuticals

$11.15

0.3 (2.77%)

CORI

Corium

$10.88

0.03 (0.28%)

TGNA

Tegna

$12.92

0.06 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

JPM

JPMorgan

$93.84

-0.28 (-0.30%)

, PNC

PNC Financial

$132.62

-0.905 (-0.68%)

10:20
09/26/17
09/26
10:20
09/26/17
10:20
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

JPM

JPMorgan

$93.84

-0.28 (-0.30%)

PNC

PNC Financial

$132.62

-0.905 (-0.68%)

AFL

Aflac

$83.23

-1.03 (-1.22%)

CATM

Cardtronics

$26.10

-3.17 (-10.83%)

CAKE

Cheesecake Factory

$41.60

0.08 (0.19%)

SHAK

Shake Shack

$31.60

-2.015 (-6.00%)

HABT

Habit Restaurants

GNCA

Genocea

$5.33

0.04 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 28

    Sep

  • 02

    Oct

  • 12

    Oct

  • 13

    Oct

  • 22

    Oct

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

DISCA

Discovery

$21.35

-0.06 (-0.28%)

, MO

Altria Group

$64.87

1.08 (1.69%)

10:20
09/26/17
09/26
10:20
09/26/17
10:20
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

DISCA

Discovery

$21.35

-0.06 (-0.28%)

MO

Altria Group

$64.87

1.08 (1.69%)

LB

L Brands

$42.77

1.87 (4.57%)

SAM

Boston Beer

$159.25

6.25 (4.09%)

BTI

British American Tobacco

$62.01

0.02 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

NKE

Nike

$53.28

0.05 (0.09%)

10:20
09/26/17
09/26
10:20
09/26/17
10:20
Options
Nike option volume heavy pre-earnings with shares flat near $53.16 »

Nike option volume heavy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

  • 04

    Oct

10:20
09/26/17
09/26
10:20
09/26/17
10:20
General news
U.S. consumer confidence dipped 0.6 points to 119.8 in September »

U.S. consumer confidence…

CCL

Carnival

$65.92

2.4185 (3.81%)

, AAPL

Apple

$150.55

-1.34 (-0.88%)

10:18
09/26/17
09/26
10:18
09/26/17
10:18
Hot Stocks
Carnival to launch digital streaming channel Ocean View »

Continues to project cash…

CCL

Carnival

$65.92

2.4185 (3.81%)

AAPL

Apple

$150.55

-1.34 (-0.88%)

AMZN

Amazon.com

$939.79

-15.31 (-1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

  • 22

    Oct

$NSD

NASDAQ Market Internals

10:17
09/26/17
09/26
10:17
09/26/17
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INFO

IHS Markit

$48.29

-0.14 (-0.29%)

10:16
09/26/17
09/26
10:16
09/26/17
10:16
Technical Analysis
Technical View: IHS Markit drops after results and outlook »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

$NYE

NYSE Market Internals

10:16
09/26/17
09/26
10:16
09/26/17
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
09/26/17
09/26
10:15
09/26/17
10:15
General news
Treasury Action: yields stalled below highs »

Treasury Action: yields…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.